Brainstorm Cell Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Brainstorm Cell Therapeutics

14/08/2023 14:32

* Brainstorm Cell Therapeutics Inc  BCLI.OQ  reported a
quarterly
adjusted loss of 27 cents​​ per share for the quarter ended in
June. The mean expectation of two analysts for the quarter was
for a loss of 15 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Brainstorm Cell Therapeutics Inc's reported EPS for the
quarter
was a loss of 27 cents​.
    * The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Brainstorm Cell Therapeutics Inc shares had fallen
by 21.4% this
quarter and lost 1.2% so far this year.
    * The company reported a quarterly loss of $10.39 million.
    * Wall Street's median 12-month price target for Brainstorm
Cell
Therapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 14 at 01:32 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.15          -0.27          Missed
 Mar. 31 2023      -0.16          -0.14          Beat
 Dec. 31 2022      -0.14          -0.13          Beat
 Sep. 30 2022      -0.18          -0.19          Missed